Weatherly Asset Management L. P. acquired a new position in shares of Celgene Co. (NASDAQ:CELG) during the 1st quarter, HoldingsChannel.com reports. The firm acquired 2,467 shares of the biopharmaceutical company’s stock, valued at approximately $233,000.
A number of other institutional investors and hedge funds have also recently made changes to their positions in CELG. Altium Wealth Management LLC lifted its stake in Celgene by 1.3% in the first quarter. Altium Wealth Management LLC now owns 8,980 shares of the biopharmaceutical company’s stock valued at $847,000 after buying an additional 115 shares during the last quarter. Janney Capital Management LLC increased its holdings in shares of Celgene by 2.9% during the fourth quarter. Janney Capital Management LLC now owns 4,219 shares of the biopharmaceutical company’s stock valued at $270,000 after purchasing an additional 120 shares during the period. Iberiabank Corp increased its holdings in shares of Celgene by 1.0% during the first quarter. Iberiabank Corp now owns 12,019 shares of the biopharmaceutical company’s stock valued at $1,134,000 after purchasing an additional 121 shares during the period. Pitcairn Co. increased its holdings in shares of Celgene by 3.0% during the fourth quarter. Pitcairn Co. now owns 4,289 shares of the biopharmaceutical company’s stock valued at $275,000 after purchasing an additional 124 shares during the period. Finally, Winthrop Advisory Group LLC increased its holdings in shares of Celgene by 4.1% during the fourth quarter. Winthrop Advisory Group LLC now owns 3,171 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 125 shares during the period. Hedge funds and other institutional investors own 72.01% of the company’s stock.
A number of research analysts have recently commented on the company. ValuEngine raised Celgene from a “sell” rating to a “hold” rating in a report on Saturday, May 4th. Barclays lowered Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price target on the stock. in a report on Friday, May 3rd. BidaskClub raised Celgene from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Mizuho set a $103.00 price target on Celgene and gave the company a “buy” rating in a report on Friday, April 5th. Finally, Cantor Fitzgerald lowered Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price target on the stock. in a report on Friday, April 5th. Twenty research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $95.96.
In other news, Director Ernest Mario bought 2,000 shares of the stock in a transaction that occurred on Tuesday, February 12th. The shares were purchased at an average cost of $89.99 per share, with a total value of $179,980.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.39% of the stock is owned by insiders.
NASDAQ:CELG traded down $0.57 during mid-day trading on Thursday, reaching $95.14. 212,681 shares of the stock were exchanged, compared to its average volume of 10,780,040. The firm has a market cap of $67.11 billion, a P/E ratio of 12.49, a PEG ratio of 0.44 and a beta of 1.68. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $97.07. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 2.42.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.45 by $0.10. The firm had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.01 billion. Celgene had a return on equity of 106.69% and a net margin of 30.10%. Celgene’s revenue was up 13.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.05 earnings per share. Sell-side analysts expect that Celgene Co. will post 9.85 EPS for the current year.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Recommended Story: What is a Futures Contract?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).